Synthetic biology: ensuring the greatest global value

Area of Science:

• Synthetic biology
• Global Health
• Bioethics

Background:

• Synthetic biology (SynBio) presents significant transformative potential, with applications for both beneficial and harmful purposes.
• Current frameworks for allocating SynBio's benefits and risks disproportionately favor wealthier nations.
• The universal nature of SynBio risks contrasts with the concentrated benefits, creating an imbalance that may lead to inequitable and inefficient outcomes.

Purpose of the Study:

• To analyze the distribution of benefits and risks associated with synthetic biology.
• To explore the potential of applying the Health Impact Fund (HIF) model to synthetic biology.
• To propose a framework for more equitable global health benefits from SynBio.

Main Methods:

• Review of synthetic biology's potential benefits and costs.
• Examination of the current global pharmaceutical industry structure.
• Adaptation of the Health Impact Fund (HIF) principles for SynBio applications.

Main Results:

• SynBio's risks are globally distributed, while benefits are primarily accrued by developed countries.
• The current risk-benefit allocation for SynBio may result in unfair and suboptimal global health decisions.
• The Health Impact Fund (HIF) model offers a viable mechanism for incentivizing equitable health impact.

Conclusions:

• The principles of the Health Impact Fund (HIF) can be productively applied to synthetic biology (SynBio) to address global health disparities.
• Implementing HIF-like mechanisms can help ensure that the benefits of SynBio are shared more equitably worldwide.
• This approach could lead to more efficient and fair global health advancements through SynBio.